Show simple item record

dc.contributor.authorDrysdale, Ken_US
dc.contributor.authorNtuli, Yen_US
dc.contributor.authorBestwick, Jen_US
dc.contributor.authorGelson, Wen_US
dc.contributor.authorAgarwal, Ken_US
dc.contributor.authorForton, Den_US
dc.contributor.authorMutimer, Den_US
dc.contributor.authorElsharkawy, AMen_US
dc.contributor.authorTownley, Cen_US
dc.contributor.authorMahomed, Fen_US
dc.contributor.authorFoster, GRen_US
dc.date.accessioned2020-11-12T10:09:47Z
dc.date.available2020-04-17en_US
dc.date.issued2020-07en_US
dc.identifier.issn0269-2813en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/68225
dc.format.extent168 - 181en_US
dc.relation.ispartofALIMENTARY PHARMACOLOGY & THERAPEUTICSen_US
dc.rights"This is the peer reviewed version of the following article: Drysdale, K, Ntuli, Y, Bestwick, J, et al. English hepatitis C registry data show high response rates to directly acting anti‐virals, even if treatment is not completed. Aliment Pharmacol Ther. 2020; 52: 168– 181. https://doi.org/10.1111/apt.15780 which has been published in final form at doi: https://doi.org/10.1111/apt.15780 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."
dc.titleEnglish hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completeden_US
dc.typeArticle
dc.identifier.doi10.1111/apt.15780en_US
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000534586200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume52en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record